Navigation Links
New Data: Efficacy and Responder Analyses of Divigel(R) (estradiol gel) 0.1 percent for the Treatment of Menopause
Date:6/30/2009

Data shows a very high percentage of women responded favorably to a bioidentical and FDA approved hormone therapy for hot flashes

MAPLE GROVE, Minn., June 30 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. presented the results of a secondary analysis to determine the response rates to three doses of transdermal Divigel(R) (estradiol gel) 0.1 percent at the recent 57th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG) in Chicago. The objectives of this secondary analysis of a phase III efficacy trial were to determine the percent of postmenopausal women who achieved a greater than 50 percent reduction in the frequency of moderate to severe vasomotor symptoms (MSVMS), or hot flashes, and to assess the change from baseline in a quality of life (Kupperman) index score that evaluated various menopausal symptoms. Divigel(R) doses studied included 1.0 mg, 0.5 mg and 0.25 mg of estradiol/day - the lowest effective approved dose of estradiol available for the treatment of MSVMS. The analysis showed a significantly greater percentage of women in all treatment groups versus placebo experienced > / = 50 percent reduction in the frequency of MSVMS at week 12. In the Divigel(R) 1.0 mg estradiol/day dosing group, 90 percent of women reported at least a 50 percent reduction in the frequency of MSVMS. Additionally, at 12 weeks, each of the doses of Divigel(R) significantly reduced the severity of menopausal symptoms identified by a quality of life index score compared to placebo.

"These data further support the safety, efficacy and tolerability of Divigel(R) as a bioidentical and FDA-approved hormone therapy for the treatment of the symptoms of menopause," said Dr. William Koltun, a clinical investigator from the Medical Center for Clinical Research in San Diego, Calif. who presented the data at ACOG. "Divigel(R) is an important addition to the options for women and their physicians in the treatmen
'/>"/>

SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Clinical trial data: Safety/efficacy of concomitant formoterol fumarate/tiotropium treating COPD
2. Five Hospitals to Share Patient Data: ICW Connects Regional Medical Centers and University Facility
3. New Government Data: Mail-Service Pharmacies Grow, But Public Programs Lag Behind
4. Shining light on sciences dark data: New venture ensures a fuller scientific record
5. Communicating Clinical Trial Data: Timing Remains Key Challenge for Marketing Teams
6. New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes
7. New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes
8. Promising Three-year Data: Saving Limbs With Drug-Eluting Stents
9. Data: Actual imaging use far below Presidents rec. 95 percent utilization rate for Medicare
10. Data: Actual imaging use far below presidents recommended 95 percent utilization rate for Medicare
11. Radiation and drug combo helps boost efficacy of lung cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email: